Cagrilintide is a lipidated, long-acting analogue of the pancreatic hormone amylin, characterized as a dual amylin and calcitonin receptor agonist. Research has examined its role in satiety signaling, gastric emptying, and energy-balance regulation in rodent models, frequently alongside incretin-pathway compounds. An acylated C20 fatty diacid side chain supports reversible albumin binding and a markedly extended duration of action relative to native amylin.
Cagrilintide is a lipidated, long-acting analogue of the pancreatic hormone amylin, characterized as a dual amylin and calcitonin receptor agonist. Research has examined its role in satiety signaling, gastric emptying, and energy-balance regulation in rodent models, frequently alongside incretin-pathway compounds. An acylated C20 fatty diacid side chain supports reversible albumin binding and a markedly extended duration of action relative to native amylin.
Cagrilintide (AM833) is supplied strictly as a reference material for in vitro and preclinical investigation. All characterization data described here is drawn from peer-reviewed literature and laboratory analysis; nothing herein constitutes a claim of clinical effect in humans.
The following domains summarize directions explored across published studies and laboratory models. Each reflects observations reported in rodent models, in vitro systems, or the peer-reviewed record.
Cagrilintide has been characterized as a non-selective agonist at amylin (AMY) and calcitonin receptors, with binding and reporter-assay potencies in the picomolar range. Research has examined how this receptor profile differs from native amylin in cellular systems.
Rodent studies have documented reductions in food intake and body-weight gain following administration of long-acting amylin analogues, with observed changes in fat-mass accumulation relative to vehicle-treated subjects.
Amylin biology research has examined delayed gastric emptying and modulation of postprandial glucagon as contributors to nutrient-handling changes observed in animal models.
Published work has investigated concurrent administration of amylin analogues with GLP-1 receptor agonists, examining whether the two pathways produce additive effects on satiety and metabolic endpoints.
Mechanistic steps below are hypothesized from in vitro assays and animal-model data reported in the literature. They describe biochemical interactions observed under controlled experimental conditions.
Cagrilintide activates amylin receptor complexes formed by the calcitonin receptor together with receptor activity-modifying proteins (RAMP1–3), initiating cAMP signaling in receptor-expressing cells.
In addition to amylin receptor activity, the analogue engages the calcitonin receptor directly. This dual profile is the basis for its description in the literature as a dual amylin and calcitonin receptor agonist.
The C20 fatty diacid side chain enables reversible albumin binding, slowing clearance and extending plasma exposure — a half-life extension strategy documented for other acylated peptide analogues.
Sequence modifications drawn from calcitonin reduce the amyloid fibril-forming tendency of the native human amylin backbone, a stability property reported in thioflavin T aggregation assays.
| Amino Acid Sequence | Lipidated 32-residue amylin analogue (disulfide-bridged, C20 diacid side chain) |
|---|---|
| Molecular Weight | 4,409.0 g/mol |
| Molecular Formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂ |
| CAS Number | 1415456-99-3 |
| Storage | −20°C long-term, 4°C short-term up to 4 weeks |
The following peer-reviewed references informed the research summaries on this page. Citations are provided for scientific context only.
This product is intended strictly for laboratory research purposes only. It is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or animal consumption. All information presented is derived from published scientific literature and is provided for educational reference only. By purchasing, the buyer affirms they are a qualified researcher or institution and assume full responsibility for the safe and lawful handling of this material.